PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG) an innovative molecular diagnostic company leveraging microRNAs as biomarkers, today announced that its Philadelphia-based laboratory has passed the survey for CLIA (Clinical Laboratory Improvement Amendments) certification in California, Rhode Island and Maryland. This brings the number of states permitting commercial molecular diagnostics tests at Rosetta Laboratories to 48. Rosetta also announces that on June 11th it filed its audited financial statements with the U.S. Securities and Exchange Commission on Form 6-K. The financial statements provide additional information with respect to the terms of the license and collaboration agreement with Prometheus Laboratories, including the potential for Rosetta to receive up to $17 million in research and development, milestone and other payments in addition to royalties on the sale of the tests.
